<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: oa--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">14735184</article-id><article-id pub-id-type="pmc">2409568</article-id><article-id pub-id-type="pii">6601586</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6601586</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical</subject></subj-group></article-categories><title-group><article-title>Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mahteme</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Hansson</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Berglund</surname><given-names>&#x000c5;</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>P&#x000e5;hlman</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Glimelius</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nygren</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Graf</surname><given-names>W</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label><sup>1</sup>Department of Surgical Sciences, Akademiska Sjukhuset, Uppsala, Sweden</aff><aff id="aff2"><label>2</label><sup>2</sup>Department of Oncology, Radiology and Clinical Immunology Akademiska Sjukhuset, Uppsala, Sweden</aff><author-notes><corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:Haile.Mahteme@kirurgi.uu.se">Haile.Mahteme@kirurgi.uu.se</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>01</month><year>2004</year></pub-date><pub-date pub-type="ppub"><day>26</day><month>01</month><year>2004</year></pub-date><volume>90</volume><issue>2</issue><fpage>403</fpage><lpage>407</lpage><history><date date-type="received"><day>26</day><month>03</month><year>2003</year></date><date date-type="rev-recd"><day>07</day><month>09</month><year>2003</year></date><date date-type="accepted"><day>13</day><month>11</month><year>2003</year></date></history><copyright-statement>Copyright 2004, Cancer Research UK</copyright-statement><copyright-year>2004</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><kwd-group><kwd>colorectal cancer</kwd><kwd>peritoneal metastases</kwd><kwd>intraperitoneal chemotherapy</kwd></kwd-group></article-meta></front><body><p>Peritoneal or local metastasis from colorectal cancer implies a poor prognosis (<xref ref-type="other" rid="bib16">Graf <italic>et al</italic>, 1991</xref>; <xref ref-type="other" rid="bib28">Mahteme <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib33">Shepherd <italic>et al</italic>, 1997</xref>; <xref ref-type="other" rid="bib1">Assersohn <italic>et al</italic>, 1999</xref>) and the treatment remains a challenging problem. Moreover, patients with peritoneal carcinomatosis often suffer from intestinal obstruction and nutritional deficit (<xref ref-type="other" rid="bib38">van Ooijen <italic>et al</italic>, 1993</xref>; <xref ref-type="other" rid="bib28">Mahteme <italic>et al</italic>, 1996</xref>). In the absence of more effective therapeutic options, systemic 5-fluorouracil (5-FU)-based chemotherapy, irinotecan or oxaliplatin is used in order to achieve a regression of the tumour and improved outcome (<xref ref-type="other" rid="bib30">Ragnhammar <italic>et al</italic>, 2001</xref>; <xref ref-type="other" rid="bib15">Glimelius, 2003</xref>). Previous studies have demonstrated that chemotherapy prolongs survival about 4&#x02013;6 months compared with supportive care alone (<xref ref-type="other" rid="bib4">Colorectal Cancer Collaborative Group, 2000</xref>). The median survival time in patients with peritoneal carcinosis treated with modern chemotherapy is in the order of 6&#x02013;12 months (<xref ref-type="other" rid="bib9">de Gramont <italic>et al</italic>, 2000</xref>). Intraperitoneal (i.p.) 5-FU infusion has been suggested as an alternative route of administration with the purpose to expose peritoneal and local tumour remnants to high cytotoxic drug levels (<xref ref-type="other" rid="bib8">Cunliffe and Sugarbaker, 1989</xref>), while only small amounts pass into systemic circulation. In recent years, there have been reports on i.p. chemotherapy treatment after cytoreductive surgery (<xref ref-type="other" rid="bib32">Schellinx <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib22">Horsell <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib7">Culliford <italic>et al</italic>, 2001</xref>). A median survival of about 30 months was recently reported in patients treated with cytoreductive surgery plus i.p. chemotherapy (<xref ref-type="other" rid="bib11">Elias <italic>et al</italic>, 2001</xref>).</p><p>The aim of this study was to explore the effects of cytoreductive surgery followed by repeated courses of i.p. chemotherapy with respect to feasibility, side effects and survival, and to compare with the results obtained using systemic chemotherapy.</p><sec sec-type="methods"><title>PATIENTS AND METHODS</title><sec><title>Patients characteristics</title><p>In all, 18 patients (nine women, nine men, mean age 54 years, range 31&#x02013;74) were included in the study. The study was approved by the regional ethics committees. The protocol was set up in 1991 and the last patient was included in September 1999. The inclusion criteria were primary colorectal adenocarcinoma (colon 16, rectal 2), with local or peritoneal tumour deposits either resectable or suitable for debulking surgery, and without hepatic or other extra abdominal tumour growth as judged from laparotomy, chest X-ray and ultrasonography&#x0002f;CT scan, age &#x0003c;75 years and American Society of Anesthesiologists (ASA) classification grades 1&#x02013;2. Informed consent was obtained from each patient. The diagnosis of the primary tumour and the metastases were verified histopathologically. One patient was not treated according to the protocol because of extensive irresectable peritoneal tumour growth. The remaining 17 patients were treated by either total macroscopic removal (11) or debulking (6) of the metastases followed by i.p. chemotherapy. In four patients, the diagnosis of local or peritoneal spread was carried out concomitant with the diagnosis of the primary tumour, and in the remaining 14 patients there was an interval of mean 19 (range 1&#x02013;52) months between the diagnosis of the primary tumour and the local&#x0002f;peritoneal recurrence. A system for classification of local&#x0002f;peritoneal spread was set up based on which all patients could be classified: (a) predominant peritoneal growth&#x000b1;smaller local deposits; (b) predominant local growth&#x000b1;smaller peritoneal deposits; and (c) predominant abdominal wall growth&#x000b1;smaller local or peritoneal deposits. Two patients were classified in group a, six in group b and 10 in group c.</p></sec><sec><title>Surgical treatment</title><p>The mean operating time was 3.7&#x02009;h (range 0.9&#x02013;6.7). The surgical procedure, the metastatic location and the treatments are detailed in <xref rid="tbl1" ref-type="table">Table 1</xref><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Surgical procedures of the 18 patients in the i.p. group</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th colspan="4" align="left" valign="top" charoff="50"><bold>Preinclusion events</bold><hr/></th><th colspan="3" align="left" valign="top" charoff="50"><bold>Events at inclusion</bold><hr/></th><th colspan="3" align="left" valign="top" charoff="50"><bold>Postinclusive events</bold><hr/></th></tr><tr><th align="left" valign="top" charoff="50"><bold>Pat.</bold></th><th align="left" valign="top" charoff="50"><bold>Primary tumour site</bold></th><th align="left" valign="top" charoff="50"><bold>Surgical procedures at primary tumour surgery</bold></th><th align="left" valign="top" charoff="50"><bold>Completing surgical events before inclusion</bold></th><th align="left" valign="top" charoff="50"><bold>Metastatic site at inclusion</bold></th><th align="left" valign="top" charoff="50"><bold>Surgical procedures at inclusion</bold></th><th align="left" valign="top" charoff="50"><bold>Macroscopically radical</bold></th><th align="left" valign="top" charoff="50"><bold>Remnant tumour location</bold></th><th align="left" valign="top" charoff="50"><bold>Additional surgical tumour procedures</bold></th><th align="left" valign="top" charoff="50"><bold>PAC reop.</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">1</td><td align="left" valign="top" charoff="50">Colon</td><td align="left" valign="top" charoff="50">Colectomy, IRA</td><td align="left" valign="top" charoff="50">Rectal res. SBR &#x000d7; 2</td><td align="left" valign="top" charoff="50">Small bowel, abdominal wall, peritoneal</td><td align="left" valign="top" charoff="50">SBR, AWR, local excision</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">SBR</td><td align="left" valign="top" charoff="50">Yes</td></tr><tr><td align="left" valign="top" charoff="50">2</td><td align="left" valign="top" charoff="50">Colon</td><td align="left" valign="top" charoff="50">R. hemicolectomy</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Ventricle, duodenum, small bowel &#x000d7; 2</td><td align="left" valign="top" charoff="50">ICR, duodenal resection, local excision, EC</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Yes</td></tr><tr><td align="left" valign="top" charoff="50">3</td><td align="left" valign="top" charoff="50">Colon</td><td align="left" valign="top" charoff="50">Sigmoid resection, SOE</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Peritoneal</td><td align="left" valign="top" charoff="50">Local excision, EC</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">4</td><td align="left" valign="top" charoff="50">Rectum</td><td align="left" valign="top" charoff="50">APR</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Pelvic wall</td><td align="left" valign="top" charoff="50">Local excision</td><td align="left" valign="top" charoff="50">No</td><td align="left" valign="top" charoff="50">Pelvic</td><td align="left" valign="top" charoff="50">Scapula and costae resection</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">5</td><td align="left" valign="top" charoff="50">Colon</td><td align="left" valign="top" charoff="50">Ileocaecal resection</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Ileocolic anastomosis, jejunum, abdominal wall</td><td align="left" valign="top" charoff="50">ICR, SBR, local excision</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">ICR &#x000d7; 2, SBR, AWR</td><td align="left" valign="top" charoff="50">Yes</td></tr><tr><td align="left" valign="top" charoff="50">6</td><td align="left" valign="top" charoff="50">Colon</td><td align="left" valign="top" charoff="50">Sigmoid resection, L. hemicolectomy, splenectomy</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Abdominal wall, small bowel</td><td align="left" valign="top" charoff="50">AWR, SBR, local excision</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">7</td><td align="left" valign="top" charoff="50">Colon</td><td align="left" valign="top" charoff="50">Sigmoid resection R. hemicolectomy</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Ileocolic anastomosis</td><td align="left" valign="top" charoff="50">ICR, local excision</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">R. hepatectomy, aorta resection, SBR</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">8</td><td align="left" valign="top" charoff="50">Colon</td><td align="left" valign="top" charoff="50">R. hemicolectomy</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Ileocolic anastomosis, sigmoid, uterus, ovary, vagina, peritoneal</td><td align="left" valign="top" charoff="50">ICR, local excision, SOE, hysterectomy, EC</td><td align="left" valign="top" charoff="50">No</td><td align="left" valign="top" charoff="50">Small bowel (peritoneal) sigmoid colon (peritoneal)</td><td align="left" valign="top" charoff="50">SBR, rectosigmoid resection, ureterolysis</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">9</td><td align="left" valign="top" charoff="50">Colon</td><td align="left" valign="top" charoff="50">L. hemicolectomy</td><td align="left" valign="top" charoff="50">Colectomy&#x0002b;IRA, SOE</td><td align="left" valign="top" charoff="50">Abdominal wall, pelvic wall, peritoneal</td><td align="left" valign="top" charoff="50">AWR, local excision, EC</td><td align="left" valign="top" charoff="50">No</td><td align="left" valign="top" charoff="50">Pelvis</td><td align="left" valign="top" charoff="50">Local excision, EC</td><td align="left" valign="top" charoff="50">Yes</td></tr><tr><td align="left" valign="top" charoff="50">10</td><td align="left" valign="top" charoff="50">Colon</td><td align="left" valign="top" charoff="50">R. hemicolectomy</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Pelvic wall, urinary bladder</td><td align="left" valign="top" charoff="50">Urinary bladder resection&#x0002b;urostoma, local excision</td><td align="left" valign="top" charoff="50">No</td><td align="left" valign="top" charoff="50">Pelvis</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">11</td><td align="left" valign="top" charoff="50">Colon</td><td align="left" valign="top" charoff="50">ICR</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Abdominal wall, ileocolic anastomosis</td><td align="left" valign="top" charoff="50">R. hemicolectomy, AWR, Local excision</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">12</td><td align="left" valign="top" charoff="50">Colon</td><td align="left" valign="top" charoff="50">Sigmoid resection</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Pelvic wall, rectum, small bowel, L.A. iliaca int, L. ureter</td><td align="left" valign="top" charoff="50">AR, iliaca int resection, local excision</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">13</td><td align="left" valign="top" charoff="50">Colon</td><td align="left" valign="top" charoff="50">R. hemicolectomy</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Abdominal wall, small bowel, sigmoid colon</td><td align="left" valign="top" charoff="50">AWR, SBR, sigmoid resection</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">AWR</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">14</td><td align="left" valign="top" charoff="50">Colon</td><td align="left" valign="top" charoff="50">Ileocaecal resection</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">R. colon, small bowel, ovary, peritoneal</td><td align="left" valign="top" charoff="50">R. hemicolectomy, SOE, local excision, EC.</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">15</td><td align="left" valign="top" charoff="50">Rectum</td><td align="left" valign="top" charoff="50">APR, sigmoideostoma</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Pelvic local, hepar, caecum</td><td align="left" valign="top" charoff="50">ICR, Liver resection, local excision</td><td align="left" valign="top" charoff="50">No</td><td align="left" valign="top" charoff="50">Pelvis</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Yes</td></tr><tr><td align="left" valign="top" charoff="50">16</td><td align="left" valign="top" charoff="50">Colon</td><td align="left" valign="top" charoff="50">Sigmoid resection, pelvic wall resection</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Ovary small bowel, colon transversum, peritoneal</td><td align="left" valign="top" charoff="50">Transversum resection, SBR, local excision, EC.</td><td align="left" valign="top" charoff="50">Yes</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">17</td><td align="left" valign="top" charoff="50">Colon</td><td align="left" valign="top" charoff="50">Sigmoid resection Hartmann resection, SBR</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Peritoneal, locally advanced</td><td align="left" valign="top" charoff="50">Local excision</td><td align="left" valign="top" charoff="50">No</td><td align="left" valign="top" charoff="50">Peritoneal</td><td align="left" valign="top" charoff="50">Rectosigmoid anastomosis</td><td align="left" valign="top" charoff="50">No</td></tr><tr><td align="left" valign="top" charoff="50">18</td><td align="left" valign="top" charoff="50">Colon</td><td align="left" valign="top" charoff="50">R. hemicolectomy</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">Peritoneal, locally advanced</td><td align="left" valign="top" charoff="50">None</td><td align="left" valign="top" charoff="50">No, No PAC</td><td align="left" valign="top" charoff="50">Peritoneal, locally advanced</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label/><p>AR&#x0003d;anterior resection; SOE&#x0003d;salpingo ofoor ectomy; APR&#x0003d;anterior perineal resection; AWR&#x0003d;abdominal wall resection; EC&#x0003d;electric cautery; ICR&#x0003d;ileocaecal resection; IRA&#x0003d;ileorectal anastomosis; PAC&#x0003d;port-A-cath; SBR&#x0003d;small bowel resection.</p></fn></table-wrap-foot></table-wrap>. At the end of surgery, a PORT-A-CATH (No. 21-2000-04, SIMS deltec, Inc., St Paul, MN, USA) was placed subcutaneously just above the periost of the lower ribs and a catheter was tunnelled through the abdominal wall and directed towards the principal tumour site. Finally, a drainage no. 18 was placed in the abdominal cavity. The drainage was plugged while the chemotherapy was given, but opened for drainage of peritoneal fluid for 1&#x02013;2&#x02009;h just before the next i.p. infusion. This drainage was removed at the end of the first treatment course.</p></sec><sec><title>Intraperitoneal chemotherapy</title><p>The i.p. chemotherapy was started the day after surgery. 5-Fluorouracil was given i.p. (550&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup>) dissolved in 500&#x02009;ml saline 0.9&#x00025;. At 60&#x02009;min after the start of the i.p. infusion, an i.v. infusion of leucovorin (LV) (60&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>) was administered. The pharmacokinetical rationale for this sequential treatment is to obtain simultaneous tissue peak concentration of 5-FU and LV (<xref ref-type="other" rid="bib34">Spears <italic>et al</italic>, 1989</xref>). The 5-FU dose was selected after a pilot study, showing that an i.p. 5-FU dose of 550&#x02009;mg&#x02009;m<sup>&#x02212;2</sup>&#x02009;day<sup>&#x02212;1</sup> during 6 days was possible to give directly after major abdominal surgery without causing an increased risk for postoperative complications (<xref ref-type="other" rid="bib18">Graf <italic>et al</italic>, 1994c</xref>). The chemotherapy treatment was given daily for 6 days with 4&#x02013;6 weeks intervals. Any possible symptoms and side effects of the treatment were registered. Before the second course of treatment, a single photon emission computed tomography (SPECT) (General Electric, GE Maxxus, Milwaukee, WI) (Technetium-labelled albumin (<sup>99</sup>Tc<sup>m</sup> Albures) at volume of 500&#x02009;ml) was performed to judge the potential distribution of the drug in the abdominal cavity. The distribution of the drug was calculated using a computer-based measurement (FBP, Nuclear Diagnostics AB, Stockholm, Sweden). After the fourth course, a clinical evaluation was carried out. Another run of four courses was given if the patients responded well, tolerated treatment and had no clinical signs of tumour progression. After the eighth course, the patients were evaluated by clinical examination and CT scans&#x0002f;MRI or a second look. In two patients, the choice of the i.p. chemotherapy courses after the first one was based on <italic>in vitro</italic> assessment of chemotherapy-resistance test (<xref ref-type="other" rid="bib6">Csoka <italic>et al</italic>, 1995</xref>). In these patients, i.p. cisplatin and i.p. irinotecan was given, respectively. The i.p. treatment was given as an outpatient procedure, except the first course, which was given directly after surgery.</p></sec><sec><title>Control group</title><p>In all, 18 patients (nine women, nine men, mean age 56 years, range 36&#x02013;69) treated for advanced colorectal adenocarcinoma within the Nordic chemotherapy trials (<xref ref-type="other" rid="bib29">Nordic Gastrointestinal Tumour Adjuvant Therapy Group, 1992</xref>; <xref ref-type="other" rid="bib13">Glimelius, 1993</xref>; <xref ref-type="other" rid="bib14">Glimelius <italic>et al</italic>, 1998</xref>) were randomly selected as a reference group. The selection was made without any knowledge of survival. The selection criteria were: (1) resected primary colorectal adenocarcinoma (colon 15, rectal 3); (2) local or peritoneal tumour deposits; (3) no lymphatic, hepatic or extra abdominal tumour growth; (4) Karnofsky performance status &#x0003e;80 (mean 90, range 80&#x02013;100); (5) treated by intravenous (i.v.) chemotherapy (eight patients received MFL and 10 received FLv). Furthermore, the control group was matched according to age and gender. The metastatic sites in this group were as follows: peritoneal (5), local (9) and peritoneal and local (4).</p></sec><sec><title>Statistical methods</title><p>Survival curves were constructed according to the Kaplan&#x02013;Mayer method and differences were analysed with the log-rank test. Differences in proportions were evaluated with Fisher exact test. A <italic>P</italic>-value below 0.05 was considered statistically significant.</p></sec></sec><sec><title>RESULTS</title><sec><title>Treatment effect</title><p>The median number of i.p. chemotherapy courses was 3 (1&#x02013;8). Four patients had pain during or immediately after the i.p. infusion; however, none of the patients terminated the planned treatment because of infusion-related pain. Leakage from the drain site was noted in one patient. Two patients suffered repetitively from nausea and vomiting during the i.p. treatment period, and transient neutropenia was noted in one patient. Of the patients, 13 terminated the planned treatment prematurely, seven of them because of catheter-related problems (local catheter infection (1), improper position (1), obstruction (5)), ileus 1, liver metastases 1, decline in general status 1 and two patients refused further treatment. Single photon emission computed tomography studies showed a median abdominal cavity distribution volume of 2896&#x02009;ml (range 32&#x02013;11&#x02009;557). In one patient, treatment was withdrawn after SPECT because of the lack of widespread distribution in abdominal cavity. In five patients the PORT-A-CATH was reoperated. There was no mortality related to surgery or to the i.p. treatment. In one patient who was not treated with cytoreductive surgery, no i.p. chemotherapy was administered.</p></sec><sec><title>Survival</title><p>The median survival in i.p. patients was 32 months (95&#x00025; confidence interval (CI) 22.2&#x02013;62.6 months), whereas in the i.v. control group it was 14 months (95&#x00025; CI 5.6&#x02013;24.9 months), (<italic>P</italic>&#x0003d;0.01, <xref ref-type="fig" rid="fig1">Figure 1</xref><fig id="fig1"><label>Figure 1</label><caption><p>Cumulative proportion surviving (Kaplan&#x02013;Meier).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="90-6601586f1"/></fig>). A 2 and 5 years survival in i.p. patients were 60 and 28&#x00025;, whereas corresponding values in the i.v. control group were 10 and 5&#x00025;. In all, 11 patients who were considered macroscopically tumour free after the tumour reduction procedure had a longer survival (34.5 months, 95&#x00025; CI 28.7&#x02013;75.7) than those who did not undergo macroscopically radical surgery (10 months, 95&#x00025; CI &#x02212;15.7 to 70.0), (<italic>P</italic>&#x0003d;0.02, <xref ref-type="fig" rid="fig2">Figure 2</xref><fig id="fig2"><label>Figure 2</label><caption><p>Cumulative proportion surviving (Kaplan&#x02013;Meier).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="gif" xlink:href="90-6601586f2"/></fig>). Five patients in whom radical surgery could be performed are still alive (median 8.3 years, range 6.8&#x02013;9.1) after surgery. One patient who underwent radical surgery survived only 4 months. One patient who was considered not to be macroscopicallly tumor free after the tumor reduction procedure is still alive and has survived 10.8 years. In total, 10 patients in whom radical surgery was not performed survived median 13 months (range 3 months&#x02013;10.8 years).</p></sec></sec><sec><title>DISCUSSION</title><p>Our experience, with treatment of peritoneal colorectal metastases, is promising. We believe patients without hematogenous metastases (e.g. liver, lung, etc) from colorectal cancer might have a survival benefit if cytoreductive surgery is combined with i.p. chemotherapy. Furthermore, a complete remission of the disease is possible for an extended period of time. It seems that a macroscopically radical tumour resection has an impact on survival.</p><p>This series is not a prospective-randomised study, and a selection of patients may of course have influenced the results. However, in an attempt to compare the locoregional treatment to standard i.v. chemotherapy, we used historical controls. The two combinations (MFL and FLv) of chemotherapy, both based on biochemical modulation of 5-FU, were equally effective with respect to survival and response rates in one trial (<xref ref-type="other" rid="bib14">Glimelius <italic>et al</italic>, 1998</xref>). It is therefore reasonable to consider these two combinations as equal and these patients thus received &#x02018;golden standard&#x02019; chemotherapy during their treatment period. However, the more recently developed combination regimen (<xref ref-type="other" rid="bib9">de Gramont <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib10">Douillard <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib31">Saltz <italic>et al</italic>, 2000</xref>) are even more effective than those used in the Nordic chemotherapy trials.</p><p>The relative importance of the i.p. chemotherapy cannot be properly assessed in the present study and further studies are needed to clarify a possible contribution of locoregional chemotherapy to the treatment effect. A possible benefit of a repeated regional treatment has been suggested since the end of 1960s (<xref ref-type="other" rid="bib27">Long <italic>et al</italic>, 1969</xref>) and several reports have been published since then (<xref ref-type="other" rid="bib36">Sugarbaker <italic>et al</italic>, 1996</xref>; <xref ref-type="other" rid="bib35">Stephens <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib3">Cavaliere <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib11">Elias <italic>et al</italic>, 2001</xref>). One of the major problems is the nonuniform distribution of the chemotherapy to tumour deposits within the abdominal cavity. The SPECTs can be valuable to analyse the drug distribution in the abdominal cavity. If there are several adhesions, the labelled albumin will accumulate only in a limited space and chemotherapy may not reach all possible metastatic sites. To prevent postoperative adhesions and an obliterated abdomen, an early start of i.p. infusion, that is, immediately after surgery or at the latest the first postoperative day may be important.</p><p>One of the concerns of i.p. chemotherapy is anastomotic dehiscence. A study in humans indicated that it is possible to give the present regimen a day after surgery without suppressing the collagen accumulation too much (<xref ref-type="other" rid="bib19">Graf <italic>et al</italic>, 1994a</xref>, <xref ref-type="other" rid="bib20">1994b</xref>). In addition, an experimental study showed an impaired healing after i.p. 5-FU, but when folinic acid was added, no further deterioration occurred (<xref ref-type="other" rid="bib17">Graf <italic>et al</italic>, 1992</xref>). However, this problem and other chemotherapy-related toxicities have been investigated in several clinical studies and this form of administration has not been associated with an increased complication rate (<xref ref-type="other" rid="bib18">Graf <italic>et al</italic>, 1994c</xref>; <xref ref-type="other" rid="bib37">Vaillant <italic>et al</italic>, 2000</xref>).</p><p>The antitumoral effect of chemotherapy is believed to be enhanced by hyperthermia (41&#x02013;42&#x000b0;C), possibly through an increase in cell membrane permeability, alteration of active drug transport, a change in cell metabolism and a decreased interstitial fluid pressure (<xref ref-type="other" rid="bib21">Hahn and Shiu, 1983</xref>; <xref ref-type="other" rid="bib26">Leunig <italic>et al</italic>, 1992</xref>; <xref ref-type="other" rid="bib25">Kong <italic>et al</italic>, 2000</xref>). Moreover, recent clinical studies have shown promising results (<xref ref-type="other" rid="bib2">Beaujard <italic>et al</italic>, 2000</xref>; <xref ref-type="other" rid="bib3">Cavaliere <italic>et al</italic>, 2000</xref>). However, there is a lack of consensus about the optimal target temperature and a finding of increased morbidity and mortality when a cytoreduction procedure has been followed by hyperthermic i.p. chemotherapy (<xref ref-type="other" rid="bib23">Jacquet <italic>et al</italic>, 1996</xref>) that warrant further studies. To optimise the i.p. treatment, choosing the appropriate chemotherapy is crucial. An important obstacle to successful treatment of solid tumours is the resistance to cytotoxic drugs (<xref ref-type="other" rid="bib39">Wright <italic>et al</italic>, 1998</xref>; <xref ref-type="other" rid="bib12">Germann, 2000</xref>; <xref ref-type="other" rid="bib24">Keppler <italic>et al</italic>, 2000</xref>). In this context, the drug resistance examination is a potential valuable tool (<xref ref-type="other" rid="bib5">Csoka <italic>et al</italic>, 1994</xref>, <xref ref-type="other" rid="bib6">1995</xref>).</p><p>In summary, a survival benefit can be achieved with cytoreductive surgery followed by repeated courses of i.p. chemotherapy. A complete remission of the disease is possible for an extended period of time. However, a longer period of follow-up is needed to establish if definite cure is possible for this category of patients and a randomised study is necessary to prove the value of this approach definitely.</p></sec></body><back><ack><p>This study was supported by the Swedish Cancer Society Project No. 4618-B01-01XAA</p></ack><ref-list><ref id="bib1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Assersohn</surname><given-names>L</given-names></name><name><surname>Norman</surname><given-names>A</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Benepal</surname><given-names>T</given-names></name><name><surname>Ross</surname><given-names>PJ</given-names></name><name><surname>Oates</surname><given-names>J</given-names></name></person-group><article-title>Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma</article-title><source>Br J Cancer</source><year>1999</year><volume>79</volume><fpage>1800</fpage><lpage>1805</lpage><!--PubMed citation query: 'Br J Cancer||79|1800||bib1|'--><pub-id pub-id-type="pmid">10206296</pub-id></citation></ref><ref id="bib2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beaujard</surname><given-names>A</given-names></name><name><surname>Glehen</surname><given-names>O</given-names></name><name><surname>Caillot</surname><given-names>J</given-names></name><name><surname>Francois</surname><given-names>Y</given-names></name><name><surname>Bienvenu</surname><given-names>J</given-names></name><name><surname>Panteix</surname><given-names>G</given-names></name><name><surname>Garbit</surname><given-names>F</given-names></name><name><surname>Grandclement</surname><given-names>E</given-names></name><name><surname>Vignal</surname><given-names>J</given-names></name><name><surname>Gilly</surname><given-names>FN</given-names></name></person-group><article-title>Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis</article-title><source>Cancer</source><year>2000</year><volume>88</volume><fpage>2512</fpage><lpage>2519</lpage><!--PubMed citation query: 'Cancer||88|2512||bib2|'--><pub-id pub-id-type="pmid">10861427</pub-id></citation></ref><ref id="bib3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cavaliere</surname><given-names>F</given-names></name><name><surname>Di Flippo</surname><given-names>F</given-names></name><name><surname>Botti</surname><given-names>C</given-names></name><name><surname>Cosimelli</surname><given-names>M</given-names></name><name><surname>Giannarelli</surname><given-names>D</given-names></name><name><surname>Aloe</surname><given-names>L</given-names></name><name><surname>Arcuri</surname><given-names>E</given-names></name><name><surname>Aromatario</surname><given-names>C</given-names></name><name><surname>Consolo</surname><given-names>S</given-names></name><name><surname>Callopoli</surname><given-names>A</given-names></name><name><surname>Laurenzi</surname><given-names>L</given-names></name><name><surname>Tedesco</surname><given-names>M</given-names></name><name><surname>Di Angelo</surname><given-names>P</given-names></name><name><surname>Giunta</surname><given-names>S</given-names></name><name><surname>Cavaliere</surname><given-names>R</given-names></name></person-group><article-title>Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis</article-title><source>Eur J Surg Oncol</source><year>2000</year><volume>26</volume><fpage>486</fpage><lpage>491</lpage><!--PubMed citation query: 'Eur J Surg Oncol||26|486||bib3|'--><pub-id pub-id-type="pmid">11016471</pub-id></citation></ref><ref id="bib4"><citation citation-type="journal"><person-group person-group-type="author"><collab>Colorectal Cancer Collaborative Group</collab></person-group><article-title>Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis</article-title><source>BMJ</source><year>2000</year><volume>321</volume><fpage>531</fpage><lpage>551</lpage><!--PubMed citation query: 'BMJ||321|531||bib4|'--></citation></ref><ref id="bib5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Csoka</surname><given-names>K</given-names></name><name><surname>Larsson</surname><given-names>R</given-names></name><name><surname>Tholander</surname><given-names>B</given-names></name><name><surname>Gerdin</surname><given-names>E</given-names></name><name><surname>dela Torre</surname><given-names>M</given-names></name><name><surname>Nygren</surname><given-names>P</given-names></name></person-group><article-title>Cytotoxic drug sensitivity testing of tumour cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA)</article-title><source>Gynecol Oncol</source><year>1994</year><volume>54</volume><fpage>163</fpage><lpage>170</lpage><!--PubMed citation query: 'Gynecol Oncol||54|163||bib5|'--><pub-id pub-id-type="pmid">7520407</pub-id></citation></ref><ref id="bib6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Csoka</surname><given-names>K</given-names></name><name><surname>Nygren</surname><given-names>P</given-names></name><name><surname>Graf</surname><given-names>W</given-names></name><name><surname>P&#x000e5;hlman</surname><given-names>L</given-names></name><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Larsson</surname><given-names>R</given-names></name></person-group><article-title>Selective sensitivity of solid tumors to suramin in primary c of tumor cells from patients</article-title><source>Int J Cancer</source><year>1995</year><volume>3</volume><fpage>356</fpage><lpage>360</lpage><!--PubMed citation query: 'Int J Cancer||3|356||bib6|'--></citation></ref><ref id="bib7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Culliford</surname><given-names>AT</given-names><suffix>4th</suffix></name><name><surname>Books</surname><given-names>AD</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Saltz</surname><given-names>LB</given-names></name><name><surname>Schwartz</surname><given-names>GK</given-names></name><name><surname>O'Reilly</surname><given-names>EM</given-names></name><name><surname>Ilson</surname><given-names>DH</given-names></name><name><surname>Kemeny</surname><given-names>NE</given-names></name><name><surname>Kelsen</surname><given-names>DP</given-names></name><name><surname>Guillem</surname><given-names>JG</given-names></name><name><surname>Wong</surname><given-names>WD</given-names></name><name><surname>Cohen</surname><given-names>AM</given-names></name><name><surname>Paty</surname><given-names>PB</given-names></name></person-group><article-title>Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer</article-title><source>Ann Surg Oncol</source><year>2001</year><volume>10</volume><fpage>787</fpage><lpage>795</lpage><!--PubMed citation query: 'Ann Surg Oncol||10|787||bib7|'--></citation></ref><ref id="bib8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cunliffe</surname><given-names>WJ</given-names></name><name><surname>Sugarbaker</surname><given-names>PH</given-names></name></person-group><article-title>Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy</article-title><source>Br J Surg</source><year>1989</year><volume>76</volume><fpage>1082</fpage><lpage>1090</lpage><!--PubMed citation query: 'Br J Surg||76|1082||bib8|'--><pub-id pub-id-type="pmid">2688796</pub-id></citation></ref><ref id="bib9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Gramont</surname><given-names>A</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Seymour</surname><given-names>M</given-names></name><name><surname>Homerin</surname><given-names>M</given-names></name><name><surname>Hmissi</surname><given-names>A</given-names></name><name><surname>Cassidy</surname><given-names>J</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Cortes-Funes</surname><given-names>H</given-names></name><name><surname>Cervantes</surname><given-names>A</given-names></name><name><surname>Freyer</surname><given-names>G</given-names></name><name><surname>Papamichael</surname><given-names>D</given-names></name><name><surname>Le Bail</surname><given-names>N</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><name><surname>Hendler</surname><given-names>D</given-names></name><name><surname>de Braud</surname><given-names>F</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Morvan</surname><given-names>F</given-names></name><name><surname>Bonetti</surname><given-names>A</given-names></name></person-group><article-title>Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>2938</fpage><lpage>2947</lpage><!--PubMed citation query: 'J Clin Oncol||18|2938||bib9|'--><pub-id pub-id-type="pmid">10944126</pub-id></citation></ref><ref id="bib10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Roth</surname><given-names>AD</given-names></name><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>James</surname><given-names>RD</given-names></name><name><surname>Karasek</surname><given-names>P</given-names></name><name><surname>Jandik</surname><given-names>P</given-names></name><name><surname>Iveson</surname><given-names>T</given-names></name><name><surname>Carmichael</surname><given-names>J</given-names></name><name><surname>Alaki</surname><given-names>M</given-names></name><name><surname>Gruia</surname><given-names>G</given-names></name><name><surname>Awad</surname><given-names>L</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name></person-group><article-title>Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trail</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>1041</fpage><lpage>1047</lpage><!--PubMed citation query: 'Lancet||355|1041||bib10|'--><pub-id pub-id-type="pmid">10744089</pub-id></citation></ref><ref id="bib11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elias</surname><given-names>D</given-names></name><name><surname>Blot</surname><given-names>F</given-names></name><name><surname>El Otmany</surname><given-names>A</given-names></name><name><surname>Antoun</surname><given-names>S</given-names></name><name><surname>Lasser</surname><given-names>P</given-names></name><name><surname>Boige</surname><given-names>V</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Ducreux</surname><given-names>M</given-names></name></person-group><article-title>Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy</article-title><source>Cancer</source><year>2001</year><volume>92</volume><fpage>71</fpage><lpage>76</lpage><!--PubMed citation query: 'Cancer||92|71||bib11|'--><pub-id pub-id-type="pmid">11443611</pub-id></citation></ref><ref id="bib12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Germann</surname><given-names>UA</given-names></name></person-group><article-title>Detection of recombinant P-glycoprotein in multidrug resistant cultured cells</article-title><source>Mol Biotechnol</source><year>2000</year><volume>14</volume><fpage>131</fpage><lpage>145</lpage><!--PubMed citation query: 'Mol Biotechnol||14|131||bib12|'--><pub-id pub-id-type="pmid">10872505</pub-id></citation></ref><ref id="bib13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glimelius</surname><given-names>B</given-names></name></person-group><article-title>Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. The gastrointestinal tumour adjuvant therapy group</article-title><source>Ann Oncol</source><year>1993</year><volume>4</volume><fpage>235</fpage><lpage>240</lpage><!--PubMed citation query: 'Ann Oncol||4|235||bib13|'--><pub-id pub-id-type="pmid">8471555</pub-id></citation></ref><ref id="bib14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Jakobsen</surname><given-names>A</given-names></name><name><surname>Graf</surname><given-names>W</given-names></name><name><surname>Berglund</surname><given-names>&#x000c5;</given-names></name><name><surname>Gadeberg</surname><given-names>C</given-names></name><name><surname>Hansen</surname><given-names>P</given-names></name><name><surname>Kjaer</surname><given-names>M</given-names></name><name><surname>Brunsgaard</surname><given-names>N</given-names></name><name><surname>Sandberg</surname><given-names>E</given-names></name><name><surname>Lindberg</surname><given-names>B</given-names></name><name><surname>Sellstrom</surname><given-names>H</given-names></name><name><surname>Lorentz</surname><given-names>T</given-names></name><name><surname>P&#x000e5;hlman</surname><given-names>L</given-names></name><name><surname>Gustavsson</surname><given-names>B</given-names></name></person-group><article-title>Bolus injection (2&#x02013;4&#x02009;min) versus short-term (10&#x02013;20&#x02009;min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial</article-title><source>Eur J Cancer</source><year>1998</year><volume>34</volume><fpage>674</fpage><lpage>678</lpage><!--PubMed citation query: 'Eur J Cancer||34|674||bib14|'--><pub-id pub-id-type="pmid">9713273</pub-id></citation></ref><ref id="bib15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glimelius</surname><given-names>B</given-names></name></person-group><article-title>Palliative treatment of patients with colorectal cancer</article-title><source>Scand J Surg</source><year>2003</year><volume>1</volume><fpage>74</fpage><lpage>83</lpage><!--PubMed citation query: 'Scand J Surg||1|74||bib15|'--></citation></ref><ref id="bib16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graf</surname><given-names>W</given-names></name><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>P&#x000e5;hlman</surname><given-names>L</given-names></name><name><surname>Bergstr&#x000f6;m</surname><given-names>R</given-names></name></person-group><article-title>Determinant of prognosis in advanced colorectal cancer</article-title><source>Eur J Cancer</source><year>1991</year><volume>27</volume><fpage>1119</fpage><lpage>1123</lpage><!--PubMed citation query: 'Eur J Cancer||27|1119||bib16|'--><pub-id pub-id-type="pmid">1835620</pub-id></citation></ref><ref id="bib17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graf</surname><given-names>W</given-names></name><name><surname>Weiber</surname><given-names>S</given-names></name><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Jiborn</surname><given-names>H</given-names></name><name><surname>P&#x000e5;hlman</surname><given-names>L</given-names></name><name><surname>Zederfeldt</surname><given-names>B</given-names></name></person-group><article-title>Influence of 5-fluorouracil and folinic acid on colonic healing: an experimental study in the rat</article-title><source>Br J Surg</source><year>1992</year><volume>79</volume><fpage>825</fpage><lpage>828</lpage><!--PubMed citation query: 'Br J Surg||79|825||bib17|'--><pub-id pub-id-type="pmid">1327397</pub-id></citation></ref><ref id="bib19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graf</surname><given-names>W</given-names></name><name><surname>Ivarsson</surname><given-names>M</given-names></name><name><surname>Gerdin</surname><given-names>B</given-names></name><name><surname>Hellsing</surname><given-names>K</given-names></name><name><surname>P&#x000e5;hlman</surname><given-names>L</given-names></name><name><surname>Glimelius</surname><given-names>B</given-names></name></person-group><article-title>The influence of early postoperative intraperitoneal chemotherapy on human wound healing</article-title><source>J Surg Res</source><year>1994a</year><volume>57</volume><fpage>394</fpage><lpage>400</lpage><!--PubMed citation query: 'J Surg Res||57|394||bib19|'--><pub-id pub-id-type="pmid">7520956</pub-id></citation></ref><ref id="bib20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graf</surname><given-names>W</given-names></name><name><surname>Weiber</surname><given-names>S</given-names></name><name><surname>Jiborn</surname><given-names>H</given-names></name><name><surname>p&#x000e5;hlman</surname><given-names>L</given-names></name><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Zederfeldt</surname><given-names>B</given-names></name></person-group><article-title>The roles of nutritional depletion and drug concentration in 5-fluorouracil induced inhibition of colonic healing</article-title><source>J Surg Res</source><year>1994b</year><volume>5</volume><fpage>452</fpage><lpage>456</lpage><!--PubMed citation query: 'J Surg Res||5|452||bib20|'--></citation></ref><ref id="bib18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graf</surname><given-names>W</given-names></name><name><surname>Westlin</surname><given-names>J-E</given-names></name><name><surname>P&#x000e5;hlman</surname><given-names>L</given-names></name><name><surname>Glimelius</surname><given-names>B</given-names></name></person-group><article-title>Adjuvant intraperitoneal 5-fluorouracil and intravenous leucovorin after colorectal cancer surgery: a randomized phase II placebo-controlled study</article-title><source>Int J Colorectal Dis</source><year>1994c</year><volume>1</volume><fpage>35</fpage><lpage>39</lpage><!--PubMed citation query: 'Int J Colorectal Dis||1|35||bib18|'--></citation></ref><ref id="bib21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>GM</given-names></name><name><surname>Shiu</surname><given-names>EC</given-names></name></person-group><article-title>Effect of pH and elevated temperatures on the cytotoxicity of some chemotherapeurtic agents on Chinese hamster cells <italic>in vitro</italic></article-title><source>Cancer Res</source><year>1983</year><volume>43</volume><fpage>5789</fpage><lpage>5791</lpage><!--PubMed citation query: 'Cancer Res||43|5789||bib21|'--><pub-id pub-id-type="pmid">6196107</pub-id></citation></ref><ref id="bib22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horsell</surname><given-names>KW</given-names></name><name><surname>Merten</surname><given-names>S</given-names></name><name><surname>Clingan</surname><given-names>P</given-names></name><name><surname>King</surname><given-names>DW</given-names></name><name><surname>Morrsis</surname><given-names>DL</given-names></name></person-group><article-title>Peritonectomy and intraperitoneal chemotherapy in appendix and colorectal cancer</article-title><source>Aust NZ J Surg</source><year>1999</year><volume>69</volume><fpage>729</fpage><lpage>732</lpage><!--PubMed citation query: 'Aust NZ J Surg||69|729||bib22|'--></citation></ref><ref id="bib23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jacquet</surname><given-names>P</given-names></name><name><surname>Stephens</surname><given-names>AD</given-names></name><name><surname>Averbach</surname><given-names>AM</given-names></name><name><surname>Chang</surname><given-names>D</given-names></name><name><surname>Ettinghausen</surname><given-names>SE</given-names></name><name><surname>Dalton</surname><given-names>RR</given-names></name><name><surname>Steves</surname><given-names>MA</given-names></name><name><surname>Sugarbaker</surname><given-names>PH</given-names></name></person-group><article-title>Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy</article-title><source>Cancer</source><year>1996</year><volume>77</volume><fpage>2622</fpage><lpage>2629</lpage><!--PubMed citation query: 'Cancer||77|2622||bib23|'--><pub-id pub-id-type="pmid">8640714</pub-id></citation></ref><ref id="bib24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keppler</surname><given-names>D</given-names></name><name><surname>Kamisako</surname><given-names>T</given-names></name><name><surname>Leier</surname><given-names>I</given-names></name><name><surname>Yunhai</surname><given-names>C</given-names></name><name><surname>Nies</surname><given-names>A</given-names></name><name><surname>Tsujii</surname><given-names>H</given-names></name><name><surname>Konig</surname><given-names>J</given-names></name></person-group><article-title>Localization, substrate specificity, and drug resistance conferred by conjugate export pumps of the MRP family</article-title><source>Adv Enzyme Regul</source><year>2000</year><volume>40</volume><fpage>339</fpage><lpage>349</lpage><!--PubMed citation query: 'Adv Enzyme Regul||40|339||bib24|'--><pub-id pub-id-type="pmid">10828358</pub-id></citation></ref><ref id="bib25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>G</given-names></name><name><surname>Braun</surname><given-names>R</given-names></name><name><surname>Dewhirst</surname><given-names>M</given-names></name></person-group><article-title>Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><fpage>4440</fpage><lpage>4445</lpage><!--PubMed citation query: 'Cancer Res||60|4440||bib25|'--><pub-id pub-id-type="pmid">10969790</pub-id></citation></ref><ref id="bib26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leunig</surname><given-names>M</given-names></name><name><surname>Goetz</surname><given-names>AE</given-names></name><name><surname>Dellian</surname><given-names>M</given-names></name><name><surname>Zetterer</surname><given-names>G</given-names></name><name><surname>Gamarra</surname><given-names>F</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name><name><surname>Messmer</surname><given-names>K</given-names></name></person-group><article-title>Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response</article-title><source>Cancer Res</source><year>1992</year><volume>52</volume><fpage>487</fpage><lpage>490</lpage><!--PubMed citation query: 'Cancer Res||52|487||bib26|'--><pub-id pub-id-type="pmid">1728421</pub-id></citation></ref><ref id="bib27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>RTL</given-names></name><name><surname>Spratt</surname><given-names>JS</given-names><suffix>Jr</suffix></name><name><surname>Dowling</surname><given-names>E</given-names></name></person-group><article-title><italic>Pseudomyxoma peritonei</italic>. New concepts in management with a report of seventeen patients</article-title><source>Am J Surg</source><year>1969</year><volume>117</volume><fpage>162</fpage><lpage>169</lpage><!--PubMed citation query: 'Am J Surg||117|162||bib27|'--><pub-id pub-id-type="pmid">5773930</pub-id></citation></ref><ref id="bib28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahteme</surname><given-names>H</given-names></name><name><surname>P&#x000e5;hlman</surname><given-names>L</given-names></name><name><surname>Glimelius</surname><given-names>B</given-names></name><name><surname>Graf</surname><given-names>W</given-names></name></person-group><article-title>Prognosis after surgery in patients with incurable rectal cancer: a population-based study</article-title><source>Br J Surg</source><year>1996</year><volume>83</volume><fpage>1116</fpage><lpage>1120</lpage><!--PubMed citation query: 'Br J Surg||83|1116||bib28|'--><pub-id pub-id-type="pmid">8869321</pub-id></citation></ref><ref id="bib29"><citation citation-type="journal"><person-group person-group-type="author"><collab>Nordic Gastrointestinal Tumour Adjuvant Therapy gRoup</collab></person-group><article-title>Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial</article-title><source>J Clin Oncol</source><year>1992</year><volume>10</volume><fpage>904</fpage><lpage>911</lpage><!--PubMed citation query: 'J Clin Oncol||10|904||bib29|'--><pub-id pub-id-type="pmid">1588370</pub-id></citation></ref><ref id="bib30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ragnhammar</surname><given-names>P</given-names></name><name><surname>Hafstr&#x000f6;m</surname><given-names>L</given-names></name><name><surname>Nygren</surname><given-names>P</given-names></name><name><surname>Glimelius</surname><given-names>B</given-names></name></person-group><article-title>A systematic overview of chemotherapy effects in colorectal cancer</article-title><source>Acta Oncol</source><year>2001</year><volume>40</volume><fpage>282</fpage><lpage>308</lpage><!--PubMed citation query: 'Acta Oncol||40|282||bib30|'--><pub-id pub-id-type="pmid">11441937</pub-id></citation></ref><ref id="bib31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saltz</surname><given-names>LB</given-names></name><name><surname>Cox</surname><given-names>JV</given-names></name><name><surname>Blanke</surname><given-names>C</given-names></name><name><surname>Rosen</surname><given-names>LS</given-names></name><name><surname>Fehrenbacher</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Maroun</surname><given-names>JA</given-names></name><name><surname>Ackland</surname><given-names>SP</given-names></name><name><surname>Locker</surname><given-names>PK</given-names></name><name><surname>Pirotta</surname><given-names>N</given-names></name><name><surname>Elfring</surname><given-names>GL</given-names></name><name><surname>Miller</surname><given-names>LL</given-names></name></person-group><article-title>Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><fpage>905</fpage><lpage>914</lpage><!--PubMed citation query: 'N Engl J Med||343|905||bib31|'--><pub-id pub-id-type="pmid">11006366</pub-id></citation></ref><ref id="bib32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schellinx</surname><given-names>ME</given-names></name><name><surname>von Meyenfeldt</surname><given-names>MF</given-names></name><name><surname>Sugerbaker</surname><given-names>PH</given-names></name></person-group><article-title>Peritoneal carcinomatosis from adenocarcinoma of the colon</article-title><source>Cancer Treat Res</source><year>1996</year><volume>81</volume><fpage>247</fpage><lpage>260</lpage><!--PubMed citation query: 'Cancer Treat Res||81|247||bib32|'--><pub-id pub-id-type="pmid">8834590</pub-id></citation></ref><ref id="bib33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>N</given-names></name><name><surname>Baxter</surname><given-names>K</given-names></name><name><surname>Love</surname><given-names>S</given-names></name></person-group><article-title>The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation</article-title><source>Gastroenterology</source><year>1997</year><volume>112</volume><fpage>1096</fpage><lpage>1102</lpage><!--PubMed citation query: 'Gastroenterology||112|1096||bib33|'--><pub-id pub-id-type="pmid">9097991</pub-id></citation></ref><ref id="bib34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spears</surname><given-names>CP</given-names></name><name><surname>Gustavsson</surname><given-names>BG</given-names></name><name><surname>Fr&#x000f6;sing</surname><given-names>R</given-names></name></person-group><article-title>Folinic acid modulation of fluorouracil: tissue kinetics of bolus administration</article-title><source>Invest New Drugs</source><year>1989</year><volume>7</volume><fpage>27</fpage><lpage>36</lpage><!--PubMed citation query: 'Invest New Drugs||7|27||bib34|'--><pub-id pub-id-type="pmid">2500406</pub-id></citation></ref><ref id="bib35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>AD</given-names></name><name><surname>Alderman</surname><given-names>R</given-names></name><name><surname>Chang</surname><given-names>D</given-names></name><name><surname>Edwards</surname><given-names>GD</given-names></name><name><surname>Esquivel</surname><given-names>J</given-names></name><name><surname>Steves</surname><given-names>M</given-names></name><name><surname>Sugarbaker</surname><given-names>PH</given-names></name></person-group><article-title>Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique</article-title><source>Ann Surg Oncol</source><year>1999</year><volume>6</volume><fpage>790</fpage><lpage>796</lpage><!--PubMed citation query: 'Ann Surg Oncol||6|790||bib35|'--><pub-id pub-id-type="pmid">10622509</pub-id></citation></ref><ref id="bib36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sugarbaker</surname><given-names>PH</given-names></name><name><surname>Schellinx</surname><given-names>ME</given-names></name><name><surname>Chang</surname><given-names>D</given-names></name><name><surname>Koslowe</surname><given-names>P</given-names></name><name><surname>von Meyerfeldt</surname><given-names>M</given-names></name></person-group><article-title>Peritoneal carcinomatosis from adenocarcinoma of the colon</article-title><source>World J Surg</source><year>1996</year><volume>20</volume><fpage>585</fpage><lpage>592</lpage><!--PubMed citation query: 'World J Surg||20|585||bib36|'--><pub-id pub-id-type="pmid">8661635</pub-id></citation></ref><ref id="bib37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vaillant</surname><given-names>J-C</given-names></name><name><surname>Nordlinger</surname><given-names>B</given-names></name><name><surname>Deuffic</surname><given-names>S</given-names></name><name><surname>Arnaud</surname><given-names>JP</given-names></name><name><surname>Pelissier</surname><given-names>E</given-names></name><name><surname>Favre</surname><given-names>JP</given-names></name><name><surname>Jaeck</surname><given-names>D</given-names></name><name><surname>Fourtanier</surname><given-names>G</given-names></name><name><surname>Grandjean</surname><given-names>JP</given-names></name><name><surname>Marre</surname><given-names>P</given-names></name><name><surname>Letoublon</surname><given-names>C</given-names></name></person-group><article-title>Adjuvant intraperitoneal 5-fluorouracil in high risk colon cancer</article-title><source>Ann Surg</source><year>2000</year><volume>231</volume><fpage>449</fpage><lpage>456</lpage><!--PubMed citation query: 'Ann Surg||231|449||bib37|'--><pub-id pub-id-type="pmid">10749603</pub-id></citation></ref><ref id="bib38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Ooijen</surname><given-names>B</given-names></name><name><surname>van der Burg</surname><given-names>M</given-names></name><name><surname>Planting</surname><given-names>A</given-names></name><name><surname>Siersema</surname><given-names>P</given-names></name><name><surname>Wiggers</surname><given-names>T</given-names></name></person-group><article-title>Surgical treatment of gastric drainage only for intestinal obstruction in patients with carcinoma of the ovary or peritoneal carcinomatosis of other origin</article-title><source>Surg Gynecol Obstet</source><year>1993</year><volume>176</volume><fpage>469</fpage><lpage>474</lpage><!--PubMed citation query: 'Surg Gynecol Obstet||176|469||bib38|'--><pub-id pub-id-type="pmid">8480270</pub-id></citation></ref><ref id="bib39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>SR</given-names></name><name><surname>Boag</surname><given-names>AH</given-names></name><name><surname>Valdimarsson</surname><given-names>G</given-names></name><name><surname>Hipfner</surname><given-names>DR</given-names></name><name><surname>Campling</surname><given-names>BG</given-names></name><name><surname>Cole</surname><given-names>SP</given-names></name><name><surname>Deeley</surname><given-names>RG</given-names></name></person-group><article-title>Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung</article-title><source>Clin Cancer Res</source><year>1998</year><volume>4</volume><fpage>2279</fpage><lpage>2289</lpage><!--PubMed citation query: 'Clin Cancer Res||4|2279||bib39|'--><pub-id pub-id-type="pmid">9748150</pub-id></citation></ref></ref-list></back></article>


